GLYCOMIMETICS INC
For the period ended Dec 31, 2023. Filed Mar 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 27, 2024
CBIO$13.65+0.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 11. EXECUTIVE COMPENSATION
| ITEM 11. | EXECUTIVE COMPENSATION |
|---|
The information required by Item 11 is hereby incorporated by reference to the relevant information to be included in the 2024 Proxy Statement under the captions “Executive Compensation” and “Non-Employee Director Compensation.”
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.